SCHEMBL6757668

SCHEMBL6757668

CC1CCC(C)N1c1cc[c]cc1

nearest known ligand 0.33

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
AR P10275 2/20 0.33
JAK3 P52333 1/20 0.32
FFAR1 O14842 1/20 0.31
F10 P00742 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3699278 0.91 ALDH1A1 (0.35)
SCHEMBL6864215 0.76 FFAR1 (0.41) FFAR1
SCHEMBL1032309 0.74 SLC18A3 (0.34) AR
SCHEMBL1028679 0.74 SLC18A3 (0.34) AR
SCHEMBL1032476 0.74 SLC18A3 (0.34) AR
SCHEMBL5557815 0.73 ALDH1A1 (0.42) ARJAK3FFAR1F10
SCHEMBL9507055 0.73 CHKA (0.41) JAK3
SCHEMBL550942 0.71 USP2 (0.55)
SCHEMBL1901765 0.71 L3MBTL3 (0.32)
SCHEMBL1031339 0.71 AR (0.42) ARJAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6716984-B2 CONTACTING PHOSPHINE COMPOUND OFTHE FORMULA XPR1R2, WHEREIN X IS A HALOGEN, WITH THE SOLID SUPPORT, RESULTING IN THE P IN THE PHOSPHINE ATTACHED INDIRECTLY OR DIRECTLY TO SOLID SUPPORT VIA A COVALENT BONDS, AND REPLACING R1 OR R2 GROUPS E. I. DU PONT DE NEMOURS AND COMPANY 2004-04-06 US claimed
US-20020077479-A1 Polymer-supported synthesis of heteroatom bidentate ligands for catalysis E. I. DU PONT DE NEMOURS AND COMPANY 2002-06-20 US claimed
US-9567355-B2 Hepatitis C inhibitors and uses thereof ABBVIE INC. (US) 2017-02-14 US disclosed
US-20160355530-A1 HEPATITIS C INHIBITORS AND USES THEREOF ABBVIE INC. 2016-12-08 US disclosed
US-9453007-B2 Hepatitis C inhibitors and uses thereof ABBVIE INC. (US) 2016-09-27 US disclosed
US-20160002213-A1 HEPATITIS C INHIBITORS AND USES THEREOF ABBVIE INC. 2016-01-07 US disclosed
US-9173887-B2 Hepatitis C inhibitors and uses thereof ABBVIE INC. (US) 2015-11-03 US disclosed
US-20140038919-A1 HEPATITIS C INHIBITORS AND USES THEREOF ABBVIE INC. (US) 2014-02-06 US disclosed
US-6716984-B2 CONTACTING PHOSPHINE COMPOUND OFTHE FORMULA XPR1R2, WHEREIN X IS A HALOGEN, WITH THE SOLID SUPPORT, RESULTING IN THE P IN THE PHOSPHINE ATTACHED INDIRECTLY OR DIRECTLY TO SOLID SUPPORT VIA A COVALENT BONDS, AND REPLACING R1 OR R2 GROUPS E. I. DU PONT DE NEMOURS AND COMPANY 2004-04-06 US disclosed
US-20020077479-A1 Polymer-supported synthesis of heteroatom bidentate ligands for catalysis E. I. DU PONT DE NEMOURS AND COMPANY 2002-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160002213-A1 HEPATITIS C INHIBITORS AND USES THEREOF HAVCR2, HCCS, SLC10A1 AR 4272/4885JAK3 187/4885FFAR1 4626/4885
US-20140038919-A1 HEPATITIS C INHIBITORS AND USES THEREOF HAVCR2, HCCS, SLC10A1 AR 4272/4885JAK3 187/4885FFAR1 4626/4885
US-20160355530-A1 HEPATITIS C INHIBITORS AND USES THEREOF HAVCR2, HCCS, SLC10A1 AR 4272/4885JAK3 187/4885FFAR1 4626/4885
US-20020077479-A1 Polymer-supported synthesis of heteroatom bidentate ligands for catalysis PARG, PCNA, PARN AR 3013/4885JAK3 3689/4885FFAR1 4323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.